Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICRO-PD
NCT03575195Phase 2Suspended
- Sponsor
- University of California, San Francisco
- Start
- Jul 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in Parkinson's disease (PD), sponsored by University of California, San Francisco. Started Jul 2019; status: suspended.
02
Drugs
rifaximin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03575195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575195.